Spruce Biosciences, Inc. Proceeds from Long-Term Debt Issued
Spruce Biosciences, Inc. (SPRB) reported Proceeds from Long-Term Debt Issued of $14.15 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2026-08-12
- Spruce Biosciences, Inc. proceeds from issuance of long-term debt for the quarter ending 2026-06-30 was $0.00.
- Spruce Biosciences, Inc. proceeds from issuance of long-term debt for the quarter ending 2026-03-31 was $14.15M.
- Spruce Biosciences, Inc. proceeds from issuance of long-term debt for the quarter ending 2025-06-30 was $0.00.
- Spruce Biosciences, Inc. proceeds from issuance of long-term debt for the quarter ending 2025-03-31 was $0.00.
- Spruce Biosciences, Inc. proceeds from issuance of long-term debt for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Spruce Biosciences, Inc. proceeds from issuance of long-term debt for fiscal 2021 was $4.99M.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $14.15M 10-Q · filed 2026-08-12 | ||
| 2026-03-31 | $14.15M 10-Q · filed 2026-05-13 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $0.00 10-Q · filed 2026-08-12 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-13 | |||
| 2022-12-31 | $0.00 10-K · filed 2023-03-16 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $0.00 derived: sum of 2 quarters · filed 2023-03-16 | $0.00 derived: sum of 3 quarters · filed 2023-03-16 | $4.99M 10-K · filed 2023-03-16 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $4.99M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $4.99M 10-Q · filed 2022-08-10 | ||
| 2021-03-31 | $4.99M 10-Q · filed 2022-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |